St. Jude Devices Cleared

St. Jude Medical(STJ Quote) said U.S. and European regulators cleared a new version of cardiac-imaging software that's designed to diagnose and treat abnormal heart rhythms.

The St. Paul, Minn.-based medical-device company said Tuesday that the Ensite System Version 7 software was approved by the Food and Drug Administration and its counterpart in Europe.

Additionally, St. Jude received the European CE Mark for the EnSite Fusion Registration Module, which combines geometric models with three-dimensional computer models to help physicians navigate catheters and display electrical information.

Product authorities in Europe also granted clearance to two St. Jude wireless devices for treating patients with heart failure and with potentially lethal heart arrhythmias. One is the Promote cardiac resynchronization therapy defibrillator and the other is the Current implantable cardioverter defibrillator.

St. Jude's shares closed down 14 cents, or 0.3%, to $44.48.